The global Neurodegenerative Disease market was valued at US$ 7003.2 million in 2023 and is anticipated to reach US$ 8704 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.

Neurodegenerative Disease Market

Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, leading to cognitive and motor impairments. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

The market for neurodegenerative disease treatments and management is driven by the increasing prevalence of these diseases, particularly with an aging population. The market's growth is also influenced by the demand for disease-modifying therapies and symptom management options to improve the quality of life for patients.

This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disease.

Report Scope

The Neurodegenerative Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neurodegenerative Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neurodegenerative Disease Market Report

Report Metric	Details
Report Name	Neurodegenerative Disease Market
Accounted market size in 2023	US$ 7003.2 million
Forecasted market size in 2030	US$ 8704 million
CAGR	3.1%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	NMDA SSRIs Dopamine Inhibitors
Segment by Application	Parkinson’s Disease Huntington Disease Amyotrophic Lateral Sclerosis Alzheimer’s Disease
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neurodegenerative Disease Market growing?

Ans: The Neurodegenerative Disease Market witnessing a CAGR of 3.1% during the forecast period 2024-2030.

What is the Neurodegenerative Disease Market size in 2030?

Ans: The Neurodegenerative Disease Market size in 2030 will be US$ 8704 million.

Who are the main players in the Neurodegenerative Disease Market report?

Ans: The main players in the Neurodegenerative Disease Market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS

What are the Application segmentation covered in the Neurodegenerative Disease Market report?

Ans: The Applications covered in the Neurodegenerative Disease Market report are Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease

What are the Type segmentation covered in the Neurodegenerative Disease Market report?

Ans: The Types covered in the Neurodegenerative Disease Market report are NMDA, SSRIs, Dopamine Inhibitors

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 NMDA

1.2.3 SSRIs

1.2.4 Dopamine Inhibitors

1.3 Market by Application

1.3.1 Global Neurodegenerative Disease Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Parkinson’s Disease

1.3.3 Huntington Disease

1.3.4 Amyotrophic Lateral Sclerosis

1.3.5 Alzheimer’s Disease

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neurodegenerative Disease Market Perspective (2019-2030)

2.2 Neurodegenerative Disease Growth Trends by Region

2.2.1 Global Neurodegenerative Disease Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Neurodegenerative Disease Historic Market Size by Region (2019-2024)

2.2.3 Neurodegenerative Disease Forecasted Market Size by Region (2025-2030)

2.3 Neurodegenerative Disease Market Dynamics

2.3.1 Neurodegenerative Disease Industry Trends

2.3.2 Neurodegenerative Disease Market Drivers

2.3.3 Neurodegenerative Disease Market Challenges

2.3.4 Neurodegenerative Disease Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neurodegenerative Disease Players by Revenue

3.1.1 Global Top Neurodegenerative Disease Players by Revenue (2019-2024)

3.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2019-2024)

3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Neurodegenerative Disease Revenue

3.4 Global Neurodegenerative Disease Market Concentration Ratio

3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2023

3.5 Neurodegenerative Disease Key Players Head office and Area Served

3.6 Key Players Neurodegenerative Disease Product Solution and Service

3.7 Date of Enter into Neurodegenerative Disease Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disease Breakdown Data by Type

4.1 Global Neurodegenerative Disease Historic Market Size by Type (2019-2024)

4.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2025-2030)

5 Neurodegenerative Disease Breakdown Data by Application

5.1 Global Neurodegenerative Disease Historic Market Size by Application (2019-2024)

5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Neurodegenerative Disease Market Size (2019-2030)

6.2 North America Neurodegenerative Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Neurodegenerative Disease Market Size by Country (2019-2024)

6.4 North America Neurodegenerative Disease Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neurodegenerative Disease Market Size (2019-2030)

7.2 Europe Neurodegenerative Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Neurodegenerative Disease Market Size by Country (2019-2024)

7.4 Europe Neurodegenerative Disease Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neurodegenerative Disease Market Size (2019-2030)

8.2 Asia-Pacific Neurodegenerative Disease Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Neurodegenerative Disease Market Size by Region (2019-2024)

8.4 Asia-Pacific Neurodegenerative Disease Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neurodegenerative Disease Market Size (2019-2030)

9.2 Latin America Neurodegenerative Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Neurodegenerative Disease Market Size by Country (2019-2024)

9.4 Latin America Neurodegenerative Disease Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neurodegenerative Disease Market Size (2019-2030)

10.2 Middle East & Africa Neurodegenerative Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Neurodegenerative Disease Market Size by Country (2019-2024)

10.4 Middle East & Africa Neurodegenerative Disease Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Detail

11.1.2 Novartis Business Overview

11.1.3 Novartis Neurodegenerative Disease Introduction

11.1.4 Novartis Revenue in Neurodegenerative Disease Business (2019-2024)

11.1.5 Novartis Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Neurodegenerative Disease Introduction

11.2.4 Pfizer Revenue in Neurodegenerative Disease Business (2019-2024)

11.2.5 Pfizer Recent Development

11.3 Merck Serono

11.3.1 Merck Serono Company Detail

11.3.2 Merck Serono Business Overview

11.3.3 Merck Serono Neurodegenerative Disease Introduction

11.3.4 Merck Serono Revenue in Neurodegenerative Disease Business (2019-2024)

11.3.5 Merck Serono Recent Development

11.4 Biogen Idec

11.4.1 Biogen Idec Company Detail

11.4.2 Biogen Idec Business Overview

11.4.3 Biogen Idec Neurodegenerative Disease Introduction

11.4.4 Biogen Idec Revenue in Neurodegenerative Disease Business (2019-2024)

11.4.5 Biogen Idec Recent Development

11.5 TEVA

11.5.1 TEVA Company Detail

11.5.2 TEVA Business Overview

11.5.3 TEVA Neurodegenerative Disease Introduction

11.5.4 TEVA Revenue in Neurodegenerative Disease Business (2019-2024)

11.5.5 TEVA Recent Development

11.6 UCB

11.6.1 UCB Company Detail

11.6.2 UCB Business Overview

11.6.3 UCB Neurodegenerative Disease Introduction

11.6.4 UCB Revenue in Neurodegenerative Disease Business (2019-2024)

11.6.5 UCB Recent Development

11.7 Boehringer Ingelheim

11.7.1 Boehringer Ingelheim Company Detail

11.7.2 Boehringer Ingelheim Business Overview

11.7.3 Boehringer Ingelheim Neurodegenerative Disease Introduction

11.7.4 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2019-2024)

11.7.5 Boehringer Ingelheim Recent Development

11.8 Sanofi

11.8.1 Sanofi Company Detail

11.8.2 Sanofi Business Overview

11.8.3 Sanofi Neurodegenerative Disease Introduction

11.8.4 Sanofi Revenue in Neurodegenerative Disease Business (2019-2024)

11.8.5 Sanofi Recent Development

11.9 GlaxoSmithKline

11.9.1 GlaxoSmithKline Company Detail

11.9.2 GlaxoSmithKline Business Overview

11.9.3 GlaxoSmithKline Neurodegenerative Disease Introduction

11.9.4 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2019-2024)

11.9.5 GlaxoSmithKline Recent Development

11.10 Livzon Pharmaceutical

11.10.1 Livzon Pharmaceutical Company Detail

11.10.2 Livzon Pharmaceutical Business Overview

11.10.3 Livzon Pharmaceutical Neurodegenerative Disease Introduction

11.10.4 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.10.5 Livzon Pharmaceutical Recent Development

11.11 Haisco Pharmaceutical

11.11.1 Haisco Pharmaceutical Company Detail

11.11.2 Haisco Pharmaceutical Business Overview

11.11.3 Haisco Pharmaceutical Neurodegenerative Disease Introduction

11.11.4 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.11.5 Haisco Pharmaceutical Recent Development

11.12 Jingxin Pharmaceutical

11.12.1 Jingxin Pharmaceutical Company Detail

11.12.2 Jingxin Pharmaceutical Business Overview

11.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Introduction

11.12.4 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.12.5 Jingxin Pharmaceutical Recent Development

11.13 Dongcheng Biochemicals

11.13.1 Dongcheng Biochemicals Company Detail

11.13.2 Dongcheng Biochemicals Business Overview

11.13.3 Dongcheng Biochemicals Neurodegenerative Disease Introduction

11.13.4 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2019-2024)

11.13.5 Dongcheng Biochemicals Recent Development

11.14 Hisun Pharmaceutical

11.14.1 Hisun Pharmaceutical Company Detail

11.14.2 Hisun Pharmaceutical Business Overview

11.14.3 Hisun Pharmaceutical Neurodegenerative Disease Introduction

11.14.4 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.14.5 Hisun Pharmaceutical Recent Development

11.15 Luye Pharma

11.15.1 Luye Pharma Company Detail

11.15.2 Luye Pharma Business Overview

11.15.3 Luye Pharma Neurodegenerative Disease Introduction

11.15.4 Luye Pharma Revenue in Neurodegenerative Disease Business (2019-2024)

11.15.5 Luye Pharma Recent Development

11.16 Ark Pharmaceutical

11.16.1 Ark Pharmaceutical Company Detail

11.16.2 Ark Pharmaceutical Business Overview

11.16.3 Ark Pharmaceutical Neurodegenerative Disease Introduction

11.16.4 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.16.5 Ark Pharmaceutical Recent Development

11.17 Kanghong Pharmaceutical

11.17.1 Kanghong Pharmaceutical Company Detail

11.17.2 Kanghong Pharmaceutical Business Overview

11.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Introduction

11.17.4 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.17.5 Kanghong Pharmaceutical Recent Development

11.18 Huahai Pharmaceutical

11.18.1 Huahai Pharmaceutical Company Detail

11.18.2 Huahai Pharmaceutical Business Overview

11.18.3 Huahai Pharmaceutical Neurodegenerative Disease Introduction

11.18.4 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.18.5 Huahai Pharmaceutical Recent Development

11.19 BORA PHARMACEUTICALS

11.19.1 BORA PHARMACEUTICALS Company Detail

11.19.2 BORA PHARMACEUTICALS Business Overview

11.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Introduction

11.19.4 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2019-2024)

11.19.5 BORA PHARMACEUTICALS Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Livzon Pharmaceutical

Haisco Pharmaceutical

JINGXIN PHARMACEUTICAL

Dongcheng Biochemicals

Hisun Pharmaceutical

Luye Pharma

Ark Pharmaceutical

Kanghong Pharmaceutical

Huahai Pharmaceutical

BORA PHARMACEUTICALS

List of Tables

Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of NMDA

Table 3. Key Players of SSRIs

Table 4. Key Players of Dopamine Inhibitors

Table 5. Global Neurodegenerative Disease Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Neurodegenerative Disease Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Neurodegenerative Disease Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Neurodegenerative Disease Market Share by Region (2019-2024)

Table 9. Global Neurodegenerative Disease Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Neurodegenerative Disease Market Share by Region (2025-2030)

Table 11. Neurodegenerative Disease Market Trends

Table 12. Neurodegenerative Disease Market Drivers

Table 13. Neurodegenerative Disease Market Challenges

Table 14. Neurodegenerative Disease Market Restraints

Table 15. Global Neurodegenerative Disease Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Neurodegenerative Disease Market Share by Players (2019-2024)

Table 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2023)

Table 18. Ranking of Global Top Neurodegenerative Disease Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Neurodegenerative Disease Product Solution and Service

Table 22. Date of Enter into Neurodegenerative Disease Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Neurodegenerative Disease Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Neurodegenerative Disease Revenue Market Share by Type (2019-2024)

Table 26. Global Neurodegenerative Disease Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Neurodegenerative Disease Revenue Market Share by Type (2025-2030)

Table 28. Global Neurodegenerative Disease Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Neurodegenerative Disease Revenue Market Share by Application (2019-2024)

Table 30. Global Neurodegenerative Disease Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Neurodegenerative Disease Revenue Market Share by Application (2025-2030)

Table 32. North America Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Neurodegenerative Disease Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Neurodegenerative Disease Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Neurodegenerative Disease Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Neurodegenerative Disease Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Neurodegenerative Disease Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Neurodegenerative Disease Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Neurodegenerative Disease Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Neurodegenerative Disease Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Neurodegenerative Disease Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Neurodegenerative Disease Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Neurodegenerative Disease Market Size by Country (2025-2030) & (US$ Million)

Table 47. Novartis Company Detail

Table 48. Novartis Business Overview

Table 49. Novartis Neurodegenerative Disease Product

Table 50. Novartis Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 51. Novartis Recent Development

Table 52. Pfizer Company Detail

Table 53. Pfizer Business Overview

Table 54. Pfizer Neurodegenerative Disease Product

Table 55. Pfizer Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 56. Pfizer Recent Development

Table 57. Merck Serono Company Detail

Table 58. Merck Serono Business Overview

Table 59. Merck Serono Neurodegenerative Disease Product

Table 60. Merck Serono Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 61. Merck Serono Recent Development

Table 62. Biogen Idec Company Detail

Table 63. Biogen Idec Business Overview

Table 64. Biogen Idec Neurodegenerative Disease Product

Table 65. Biogen Idec Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 66. Biogen Idec Recent Development

Table 67. TEVA Company Detail

Table 68. TEVA Business Overview

Table 69. TEVA Neurodegenerative Disease Product

Table 70. TEVA Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 71. TEVA Recent Development

Table 72. UCB Company Detail

Table 73. UCB Business Overview

Table 74. UCB Neurodegenerative Disease Product

Table 75. UCB Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 76. UCB Recent Development

Table 77. Boehringer Ingelheim Company Detail

Table 78. Boehringer Ingelheim Business Overview

Table 79. Boehringer Ingelheim Neurodegenerative Disease Product

Table 80. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 81. Boehringer Ingelheim Recent Development

Table 82. Sanofi Company Detail

Table 83. Sanofi Business Overview

Table 84. Sanofi Neurodegenerative Disease Product

Table 85. Sanofi Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 86. Sanofi Recent Development

Table 87. GlaxoSmithKline Company Detail

Table 88. GlaxoSmithKline Business Overview

Table 89. GlaxoSmithKline Neurodegenerative Disease Product

Table 90. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 91. GlaxoSmithKline Recent Development

Table 92. Livzon Pharmaceutical Company Detail

Table 93. Livzon Pharmaceutical Business Overview

Table 94. Livzon Pharmaceutical Neurodegenerative Disease Product

Table 95. Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 96. Livzon Pharmaceutical Recent Development

Table 97. Haisco Pharmaceutical Company Detail

Table 98. Haisco Pharmaceutical Business Overview

Table 99. Haisco Pharmaceutical Neurodegenerative Disease Product

Table 100. Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 101. Haisco Pharmaceutical Recent Development

Table 102. Jingxin Pharmaceutical Company Detail

Table 103. Jingxin Pharmaceutical Business Overview

Table 104. Jingxin Pharmaceutical Neurodegenerative Disease Product

Table 105. Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 106. Jingxin Pharmaceutical Recent Development

Table 107. Dongcheng Biochemicals Company Detail

Table 108. Dongcheng Biochemicals Business Overview

Table 109. Dongcheng Biochemicals Neurodegenerative Disease Product

Table 110. Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 111. Dongcheng Biochemicals Recent Development

Table 112. Hisun Pharmaceutical Company Detail

Table 113. Hisun Pharmaceutical Business Overview

Table 114. Hisun Pharmaceutical Neurodegenerative Disease Product

Table 115. Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 116. Hisun Pharmaceutical Recent Development

Table 117. Luye Pharma Company Detail

Table 118. Luye Pharma Business Overview

Table 119. Luye Pharma Neurodegenerative Disease Product

Table 120. Luye Pharma Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 121. Luye Pharma Recent Development

Table 122. Ark Pharmaceutical Company Detail

Table 123. Ark Pharmaceutical Business Overview

Table 124. Ark Pharmaceutical Neurodegenerative Disease Product

Table 125. Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 126. Ark Pharmaceutical Recent Development

Table 127. Kanghong Pharmaceutical Company Detail

Table 128. Kanghong Pharmaceutical Business Overview

Table 129. Kanghong Pharmaceutical Neurodegenerative Disease Product

Table 130. Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 131. Kanghong Pharmaceutical Recent Development

Table 132. Huahai Pharmaceutical Company Detail

Table 133. Huahai Pharmaceutical Business Overview

Table 134. Huahai Pharmaceutical Neurodegenerative Disease Product

Table 135. Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 136. Huahai Pharmaceutical Recent Development

Table 137. BORA PHARMACEUTICALS Company Detail

Table 138. BORA PHARMACEUTICALS Business Overview

Table 139. BORA PHARMACEUTICALS Neurodegenerative Disease Product

Table 140. BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 141. BORA PHARMACEUTICALS Recent Development

Table 142. Research Programs/Design for This Report

Table 143. Key Data Information from Secondary Sources

Table 144. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neurodegenerative Disease Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Neurodegenerative Disease Market Share by Type: 2023 VS 2030

Figure 3. NMDA Features

Figure 4. SSRIs Features

Figure 5. Dopamine Inhibitors Features

Figure 6. Global Neurodegenerative Disease Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Neurodegenerative Disease Market Share by Application: 2023 VS 2030

Figure 8. Parkinson’s Disease Case Studies

Figure 9. Huntington Disease Case Studies

Figure 10. Amyotrophic Lateral Sclerosis Case Studies

Figure 11. Alzheimer’s Disease Case Studies

Figure 12. Neurodegenerative Disease Report Years Considered

Figure 13. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Neurodegenerative Disease Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Neurodegenerative Disease Market Share by Region: 2023 VS 2030

Figure 16. Global Neurodegenerative Disease Market Share by Players in 2023

Figure 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2023

Figure 19. North America Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Neurodegenerative Disease Market Share by Country (2019-2030)

Figure 21. United States Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Neurodegenerative Disease Market Share by Country (2019-2030)

Figure 25. Germany Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Neurodegenerative Disease Market Share by Region (2019-2030)

Figure 33. China Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Neurodegenerative Disease Market Share by Country (2019-2030)

Figure 41. Mexico Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Neurodegenerative Disease Market Share by Country (2019-2030)

Figure 45. Turkey Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 48. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 49. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 50. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 51. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 52. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 53. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 54. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 55. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 56. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 57. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 58. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 59. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 60. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 61. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 62. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 63. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 64. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 65. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Cerebral Palsy Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-36K2790

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Chorea Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-22U5801

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Autism Diagnostic Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-29P12566

Mon Mar 25 00:00:00 UTC 2024

Add to Cart

Spinal Cord Stimulation Devices - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-11Z11048

Thu Mar 21 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions